Advertisement
U.S. markets close in 6 hours 2 minutes
  • S&P 500

    4,601.07
    -3.30 (-0.07%)
     
  • Dow 30

    36,244.93
    -2.94 (-0.01%)
     
  • Nasdaq

    14,360.53
    -43.45 (-0.30%)
     
  • Russell 2000

    1,879.47
    -1.35 (-0.07%)
     
  • Crude Oil

    71.28
    +0.05 (+0.07%)
     
  • Gold

    2,004.40
    -10.10 (-0.50%)
     
  • Silver

    23.17
    -0.11 (-0.48%)
     
  • EUR/USD

    1.0755
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    4.2640
    +0.0190 (+0.45%)
     
  • GBP/USD

    1.2568
    +0.0017 (+0.14%)
     
  • USD/JPY

    146.2200
    +1.3270 (+0.92%)
     
  • Bitcoin USD

    41,906.64
    -1,961.71 (-4.47%)
     
  • CMC Crypto 200

    863.41
    -51.40 (-5.62%)
     
  • FTSE 100

    7,532.36
    -22.11 (-0.29%)
     
  • Nikkei 225

    32,791.80
    +483.94 (+1.50%)
     

Form 8.3 - Horizon Therapeutics plc

LONDON, September 28, 2023--(BUSINESS WIRE)--

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

Name of person dealing (Note 1)

Millennium International Management LP

Company dealt in

Horizon Therapeutics plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

IE00BQPVQZ61

Date of dealing

27th September 2023

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

4,484,508

(1.959%)

4,473

(0.002%)

(2) Derivatives (other than options)

-

496,000

(0.217%)

(3) Options and agreements to purchase/sell

822,900

(0.359%)

1,077,900

(0.471%)

Total

5,307,408

(2.318%)

1,578,373

(0.689%)

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

Ap20

1. DEALINGS (Note 4)

(a) Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (USD) (Note 5)

Sale

83

115.74

Purchase

83

115.70

Purchase

2,628

115.79

Purchase

7,188

115.75

Purchase

27,310

115.74

Purchase

30

115.85

Purchase

1,334

115.78

Purchase

54

115.84

Purchase

82

115.80

Purchase

174

115.81

Purchase

11,151

115.73

Purchase

8,403

115.72

Purchase

182

115.77

Purchase

153

115.82

Purchase

709

115.76

Sale

7,189

115.70

Purchase

4,077

115.71

Sale

43

115.74

Purchase

3,879

115.75

Purchase

1,123

115.74

Purchase

40

115.78

(b) Derivatives transactions (other than options transactions)

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit (USD)

(Note 5)

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

(USD)

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

(ii) Exercising

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

(d) Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

Ap21

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None.

Is a Supplemental Form 8 attached? (Note 9) YES

Date of disclosure

28th September 2023

Contact name

Stephen Glasper

Telephone number

+44 203 398 2166

If a connected EFM, name of offeree/offeror with which connected

If a connected EFM, state nature of connection (Note 10)

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1. KEY INFORMATION

Full name of person making
disclosure:

Millennium International Management LP

Name of offeror/offeree in relation
to whose relevant securities the
disclosure relates:

Horizon Therapeutics plc

2. STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of
relevant
security

Product
description
e.g. call
option

Written or
purchased

Number of
securities to
which option
or derivative
relates

Exercise
price
per unit

(USD)

Type
e.g.
American,
European
etc.

Expiry
date

IE00BQPVQZ61

Put Option

Purchased

300

80.00

American

1/17/2025

IE00BQPVQZ61

Put Option

Purchased

100,300

90.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Written

284,900

60.00

American

12/15/2023

IE00BQPVQZ61

Put Option

Written

100,000

65.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

55,000

70.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Written

41,500

45.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Purchased

250,000

85.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Purchased

152,500

110.00

American

11/17/2023

IE00BQPVQZ61

Call Option

Purchased

4,500

110.00

American

10/20/2023

IE00BQPVQZ61

Call Option

Purchased

100,000

100.00

American

12/15/2023

IE00BQPVQZ61

Call Option

Written

100,000

110.00

American

12/15/2023

IE00BQPVQZ61

Call Option

Written

3,400

100.00

American

10/20/2023

IE00BQPVQZ61

Call Option

Purchased

2,800

100.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

150,000

85.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

2,600

90.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

40,900

100.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

41,500

65.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Written

600

100.00

American

10/20/2023

IE00BQPVQZ61

Put Option

Purchased

100,000

70.00

American

11/17/2023

IE00BQPVQZ61

Call Option

Purchased

200

115.00

American

12/15/2023

IE00BQPVQZ61

Put Option

Written

100,000

60.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Purchased

35,200

110.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Written

54,800

115.00

American

1/19/2024

IE00BQPVQZ61

Call Option

Written

400

105.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Written

400

105.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

27,000

95.00

American

10/20/2023

IE00BQPVQZ61

Call Option

Purchased

300

115.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

11,800

115.00

American

11/17/2023

IE00BQPVQZ61

Put Option

Purchased

5,300

115.00

American

11/17/2025

IE00BQPVQZ61

Put Option

Purchased

5,600

115.00

American

1/19/2024

IE00BQPVQZ61

Put Option

Purchased

115,000

115.00

American

10/20/2023

IE00BQPVQZ61

Put Option

Purchased

11,400

115.00

American

12/15/2023

IE00BQPVQZ61

Put Option

Purchased

600

115.00

American

2/16/2023

IE00BQPVQZ61

Put Option

Purchased

600

115.00

American

3/15/2024

IE00BQPVQZ61

Put Option

Purchased

400

115.00

American

5/17/2023

IE00BQPVQZ61

Put Option

Purchased

1,000

115.00

American

10/27/2023

3. AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4. RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS’ AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230928122718/en/

Contacts

Millennium Partners, L.P.

Advertisement